Skip to main content
Fig. 5 | Microbiome

Fig. 5

From: The effects of inhaled aztreonam on the cystic fibrosis lung microbiome

Fig. 5

Assessment of microbiome differences POST AZLI initiation in responders (R) (n = 54) vs non-responders (NR) (n = 16). a No significant differences were observed in Shannon diversity index. b Similarly, no significant differences were in Bray-Curtis PCoA plot as measured by PERMANOVA (p = 0.06). When permutations were constrained by patient, the p value increased dramatically to (p = 1.0). c–e Box plots showing significant differences, as demonstrated by the Wilcoxon rank-sum test, in the log abundance of organisms identified at the OTU level present in >20% of samples. Samples on systemic therapies were filtered out

Back to article page